Table 2.
Concentration of sterol intermediates in patients with mild (N = 14) and severe (N = 48) COVID-19 measured at hospital admission
| Sterol name | Concentration [ng/mL] |
|||||
|---|---|---|---|---|---|---|
| T1 |
T2 |
T3 |
||||
| Mild | Severe | Mild | Severe | Mild | Severe | |
| lanosterol | 48.34 ± 100.98 | 19.95 ± 11.77 | 52.65 ± 77.73 | 36.21 ± 62.40 | 48.76 ± 80.54 | 24.42 ± 16.60 |
| 24,25-dihydrolanosterol | 4.15 ± 3.83 | 40.46 ± 228.38 | 7.18 ± 6.54 | 36.09 ± 178.55 | 7.63 ± 9.27 | 33.92 ± 180.78 |
| T-MAS | 31.18 ± 11.46 | 36.13 ± 11.16 | 45.17 ± 22.25 | 47.65 ± 38.81 | 43.02 ± 21.14 | 44.32 ± 18.36 |
| dihydro-T-MAS | 38.83 ± 38.33 | 48.17 ± 44.41 | 68.10 ± 69.70 | 58.52 ± 53.27 | 63.56 ± 72.67 | 54.53 ± 43.83 |
| zymosterol | 234.29 ± 146.37 | 196.70 ± 107.56 | 387.69 ± 487.68 | 291.07 ± 234.56 | 266.49 ± 224.34 | 300.75 ± 262.96 |
| zymostenol | 593.27 ± 263.01 | 546.95 ± 352.53 | 819.32 ± 521.05 | 696.03 ± 446.04 | 752.53 ± 419.62 | 569.46 ± 314.30 |
| 24-dehydrolathosterol | 51.84 ± 30.73 | 36.94 ± 20.31 | 81.06 ± 96.69 | 49.50 ± 40.53 | 69.65 ± 70.39 | 56.50 ± 32.96 |
| lathosterol | 781.71 ± 677.21 | 974.93 ± 524.65 | 1200.01 ± 1475.55 | 1050.77 ± 565.37 | 1258.76 ± 979.63 | 1171.96 ± 764.83 |
| desmosterol | 538.41 ± 548.88 | 302.72 ± 112.58 | 577.32 ± 516.68 | 352.64 ± 180.33 | 630.24 ± 957.82 | 465.34 ± 195.47 |
| cholesterol | 1156.96 ± 385.43 | 1112.98 ± 271.54 | 1442.01 ± 398.03 | 1233.75 ± 335.29 | 1107.95 ± 267.97 | 1253.15 ± 336.29 |
Data are represented as mean ± SD. See also Table S3. SD, standard deviation.